{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:04:35Z","timestamp":1764785075147},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.gore.2023.101157","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T17:18:50Z","timestamp":1677777530000},"page":"101157","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO"],"prefix":"10.1016","volume":"46","author":[{"given":"Beryl L.","family":"Manning-Geist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Flint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.gore.2023.101157_b0005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.gore.2023.101157_b0010","unstructured":"Surveillance Feasible for Women Deferring Prophylactic Salpingo-Oophorectomy. HealthDay News 2022."},{"issue":"2","key":"10.1016\/j.gore.2023.101157_b0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2019.08.034","article-title":"A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy","volume":"155","author":"Gronwald","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2023.101157_b0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Henderson","year":"2018","journal-title":"JAMA."},{"issue":"3","key":"10.1016\/j.gore.2023.101157_b0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"Suppl 10","key":"10.1016\/j.gore.2023.101157_b0030","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann. Oncol."},{"issue":"10290","key":"10.1016\/j.gore.2023.101157_b0035","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.gore.2023.101157_b0040","unstructured":"NCCN Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 2.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Published 202Accessed January 22, 2023."},{"key":"10.1016\/j.gore.2023.101157_b0045","article-title":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2","author":"Philpott","year":"2022","journal-title":"J Med Genet."},{"issue":"13","key":"10.1016\/j.gore.2023.101157_b0050","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"United kingdom familial ovarian cancer screening study collaborators. evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2023.101157_b0055","unstructured":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics. SEER Relative Survival Rates by Time Since Diagnosis, 2000-2018, National Center for Health Statistics, CDC. https:\/\/seer.cancer.gov\/statistics-network\/explorer."},{"issue":"14","key":"10.1016\/j.gore.2023.101157_b0060","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials","volume":"23","author":"Skates","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2023.101157_b0065","doi-asserted-by":"crossref","unstructured":"Smith MJ., Gerber D., Olsen A. et al. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations. Am. J. Obstet. Gynecol. 2021;225 5 508 e501-508 e510.","DOI":"10.1016\/j.ajog.2021.06.070"},{"issue":"8","key":"10.1016\/j.gore.2023.101157_b0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of Life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gore.2023.101157_b0075","doi-asserted-by":"crossref","unstructured":"van Nagell JR, Jr., Miller RW, DeSimone CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011;118 6 1212-1221.","DOI":"10.1097\/AOG.0b013e318238d030"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T18:00:41Z","timestamp":1715364041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":15,"alternative-id":["S2352578923000267"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101157","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101157"}}